Published 3 months ahead of its official implementation, the Podiatry Board of Australia (The Board) released the revised registration standard for endorsement for scheduled medicines on 30th April 2018. The new guidelines will be implemented on 1st August 2018.
The Board asks all podiatrists and podiatric surgeons to review all documents pertaining to the changes. Any podiatrist or podiatric surgeon applying to have their registration endorsed for scheduled medicines under section 94 of the National Law or whose registration is endorsed for schedule medicines will have to act in accordance with these new set of guidelines.
The key changes to the registration standard are:
- It has clearer wording and structure, including a section with definitions.
- It includes explicit reference to the NPS Medicinewise Prescribing Competencies Framework which describes the competencies that health professionals need to prescribe medicines judiciously, appropriately, safely and effectively in the Australian healthcare system.
- It has two pathways to endorsement – Pathway A and Pathway B:
- Pathway A is a new contemporary pathway which enables students who complete an accredited and approved program of study for endorsement for scheduled medicines to be qualified for endorsement on graduation, and
- Pathway B is similar to the current Pathway 2 with some modifications, including a change to the evidence to be submitted with an application for endorsement (a portfolio of evidence instead of 40 log sheets).
It is important to note that there are also changes to the National podiatry scheduled medicines list attached to the new registration standard. For more information, visit the Board’s website for documents and flowcharts that will further explain the adjustments in the system. Further information will be published on the website once the new standards take effect.
Click here for the scheduled medicines registration standard, guidelines and FAQ documents.
Image: Visual Hunt
More articles on My Health Career: